Back to resultsAn Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. (CRESCENDO)
Primary Purpose
Chronic Obstructive Pulmonary Disease (COPD)
Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Mitiperstat (AZD4831)
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease (COPD) focused on measuring Mitiperstat, AZD4831, Myeloperoxidase, MPO, Myeloperoxidase inhibitor, COPD, Chronic Obstructive Pulmonary Disease, Lung function
Eligibility Criteria
Inclusion Criteria:
- Provision of informed consent.
- Participants must be deemed as high risk of exacerbations as defined by: >= 1 moderate or severe exacerbation in the previous 24 months; or frequent productive cough; or post-bronchodilator (BD) forced expiratory volume in the first second (FEV1) < 50% predicted.
- Participants must be 40-80 years of age inclusive, at the time of signing informed consent form (ICF).
- Participants who have a confirmed primary diagnosis of moderate to severe COPD.
- Participants who are current or ex-smokers with a tobacco history of ≥ 10 pack-years.
Participants who have a documented stable regimen of triple therapy or dual therapy for
≥ 3 months prior to enrolment.
- Body mass index within the range 18 to 40 kg/m2 (inclusive).
Exclusion Criteria:
- Participants with a positive diagnostic lateral flow test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) at Study Visit 1 (SV1) or Study Visit 3 (SV3).
- Participants with a significant Coronavirus Disease 2019 (COVID-19) illness within 6 months of enrolment.
- As judged by the investigator, any evidence of any active medical or psychiatric condition or other reason (at SV1 [screening] and SV3 [pre-dose]) which in the investigator's opinion makes it undesirable for the participant to participate in the study.
- Current diagnosis of asthma or past diagnosis of asthma which persisted beyond the age of 25 years.
- Clinically important pulmonary disease other than COPD.
- Any other clinically relevant abnormal findings on physical examination, laboratory testing including haematology, coagulation, serum chemistry, or urinalysis; or chest CT scan at screening or randomisation, which in the opinion of the investigator or medical monitor may compromise the safety of the participant in the study or interfere with evaluation of the study intervention or reduce the participant's ability to participate in the study.
- History of a clinically significant infection (viral, bacterial, or fungal; defined as requiring systemic antibiotics, antiviral, or antifungal medication for > 7 days) within 4 weeks prior to SV3 (Day 1) (including unexplained diarrhoea) or clinical suspicion of infection at time of dosing.
Sites / Locations
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research Site
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research Site
- Research SiteRecruiting
- Research SiteRecruiting
- Research Site
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research Site
- Research SiteRecruiting
- Research Site
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research Site
- Research Site
- Research SiteRecruiting
- Research Site
- Research Site
- Research Site
- Research Site
- Research SiteRecruiting
- Research SiteRecruiting
- Research Site
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research Site
- Research Site
- Research SiteRecruiting
- Research SiteRecruiting
- Research Site
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research Site
- Research Site
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
- Research Site
- Research SiteRecruiting
- Research SiteRecruiting
- Research SiteRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Placebo
Mitiperstat (AZD4831)
Arm Description
Approximately 144 participants will be randomised to receive placebo.
Approximately 144 participants will be randomised to receive mitiperstat (AZD4831).
Outcomes
Primary Outcome Measures
To evaluate the effect of mitiperstat (AZD4831) as compared to placebo on the time to first COPD Composite Exacerbation (CompEx) event in patients with moderate to severe COPD.
All patients randomised to either active or placebo arm.
Secondary Outcome Measures
To assess the pharmacokinetics (PK) of mitiperstat (AZD4831) in patients with moderate to severe COPD.
Measurement of Maximum Plasma Concentration (Cmax) at pre-randomisation (baseline visit) and week 12 (or at early discontinuation visit due to rash).
To assess the PK of mitiperstat (AZD4831) in patients with moderate to severe COPD
Measurement of Time to Reach Maximum Plasma Concentration (Tmax) at pre-randomisation (baseline visit) and week 12 (or at early discontinuation visit due to rash).
To evaluate the effect of mitiperstat (AZD4831) as compared to placebo on the time to first moderate or severe exacerbation.
All patients randomised to either active or placebo arms.
To assess the effects of mitiperstat (AZD4831) as compared to placebo on post-bronchodilator (BD) forced expiratory volume in the first second (FEV1) in patients with moderate to severe COPD.
All patients randomised to either active or placebo arms. Change in post-BD FEV1.
To assess the effect of mitiperstat (AZD4831) compared to placebo on respiratory symptoms in patients with moderate to severe COPD.
All patients randomised to either active or placebo arms. Change from baseline in EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) which is a 14-item ePRO instrument developed to assess the frequency, severity and duration of COPD exacerbations.
To assess the effect of mitiperstat (AZD4831) compared to placebo on respiratory symptoms in patients with moderate to severe COPD.
All patients randomised to either active or placebo arms. Change from baseline in Breathlessness, Cough and Sputum Score (BCSS) with the 5-point Likert scale ranging from 0 (no symptoms) to 4 (severe symptoms).
To assess the effect of mitiperstat (AZD4831) compared to placebo on respiratory symptoms in patients with moderate to severe COPD.
All patients randomised to either active or placebo arms. Change from baseline in cough Visual Analogue Scale (cough VAS) with the 100-point linear scale ranging from 0 (no cough) to 100 (worst cough).
To assess the effect of mitiperstat (AZD4831) compared to placebo in disease impact in patients with moderate to severe COPD.
All patients randomised to either active or placebo arms. Change from baseline in total COPD Assessment Test (CAT) with the 5-point Likert scale ranging from 0 (no symptoms/no impact) to 5 (severe symptoms/impact).
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05492877
Brief Title
An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
Acronym
CRESCENDO
Official Title
A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of Mitiperstat (AZD4831), for 12-24 Weeks, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 14, 2022 (Actual)
Primary Completion Date
May 27, 2024 (Anticipated)
Study Completion Date
May 27, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a research study to evaluate the efficacy and safety of the investigational drug Mitiperstat (AZD4831) in adult patients with chronic obstructive pulmonary disease.
Detailed Description
Study D6582C00001 is a phase IIa randomised, double blind, placebo controlled, parallel arm study to evaluate the efficacy and safety of Mitiperstat (AZD4831) in adult participants with moderate to severe chronic obstructive pulmonary disease.
Approximately 100 sites globally will participate in this study. Approximately 288 participants will be randomised to two treatment groups; Mitiperstat (AZD4831) vs placebo in a 1:1 ratio.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Obstructive Pulmonary Disease (COPD)
Keywords
Mitiperstat, AZD4831, Myeloperoxidase, MPO, Myeloperoxidase inhibitor, COPD, Chronic Obstructive Pulmonary Disease, Lung function
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Participants will be randomised to receive either Mitiperstat (AZD4831) or placebo.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
288 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Approximately 144 participants will be randomised to receive placebo.
Arm Title
Mitiperstat (AZD4831)
Arm Type
Experimental
Arm Description
Approximately 144 participants will be randomised to receive mitiperstat (AZD4831).
Intervention Type
Drug
Intervention Name(s)
Mitiperstat (AZD4831)
Intervention Description
Oral dosage, once daily.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Oral dosage, once daily.
Primary Outcome Measure Information:
Title
To evaluate the effect of mitiperstat (AZD4831) as compared to placebo on the time to first COPD Composite Exacerbation (CompEx) event in patients with moderate to severe COPD.
Description
All patients randomised to either active or placebo arm.
Time Frame
From baseline to up to 24 weeks
Secondary Outcome Measure Information:
Title
To assess the pharmacokinetics (PK) of mitiperstat (AZD4831) in patients with moderate to severe COPD.
Description
Measurement of Maximum Plasma Concentration (Cmax) at pre-randomisation (baseline visit) and week 12 (or at early discontinuation visit due to rash).
Time Frame
Baseline and week 12 (or at early discontinuation visit due to rash)
Title
To assess the PK of mitiperstat (AZD4831) in patients with moderate to severe COPD
Description
Measurement of Time to Reach Maximum Plasma Concentration (Tmax) at pre-randomisation (baseline visit) and week 12 (or at early discontinuation visit due to rash).
Time Frame
Baseline and week 12 (or at early discontinuation visit due to rash)
Title
To evaluate the effect of mitiperstat (AZD4831) as compared to placebo on the time to first moderate or severe exacerbation.
Description
All patients randomised to either active or placebo arms.
Time Frame
From baseline to up to week 24
Title
To assess the effects of mitiperstat (AZD4831) as compared to placebo on post-bronchodilator (BD) forced expiratory volume in the first second (FEV1) in patients with moderate to severe COPD.
Description
All patients randomised to either active or placebo arms. Change in post-BD FEV1.
Time Frame
From baseline to week 12
Title
To assess the effect of mitiperstat (AZD4831) compared to placebo on respiratory symptoms in patients with moderate to severe COPD.
Description
All patients randomised to either active or placebo arms. Change from baseline in EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) which is a 14-item ePRO instrument developed to assess the frequency, severity and duration of COPD exacerbations.
Time Frame
From baseline to week 12 and week 24
Title
To assess the effect of mitiperstat (AZD4831) compared to placebo on respiratory symptoms in patients with moderate to severe COPD.
Description
All patients randomised to either active or placebo arms. Change from baseline in Breathlessness, Cough and Sputum Score (BCSS) with the 5-point Likert scale ranging from 0 (no symptoms) to 4 (severe symptoms).
Time Frame
From baseline to week 12 and week 24
Title
To assess the effect of mitiperstat (AZD4831) compared to placebo on respiratory symptoms in patients with moderate to severe COPD.
Description
All patients randomised to either active or placebo arms. Change from baseline in cough Visual Analogue Scale (cough VAS) with the 100-point linear scale ranging from 0 (no cough) to 100 (worst cough).
Time Frame
From baseline to week 12 and week 24
Title
To assess the effect of mitiperstat (AZD4831) compared to placebo in disease impact in patients with moderate to severe COPD.
Description
All patients randomised to either active or placebo arms. Change from baseline in total COPD Assessment Test (CAT) with the 5-point Likert scale ranging from 0 (no symptoms/no impact) to 5 (severe symptoms/impact).
Time Frame
From baseline to Week 12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Provision of informed consent.
Participants must be deemed as high risk of exacerbations as defined by: >= 1 moderate or severe exacerbation in the previous 24 months; or frequent productive cough; or post-bronchodilator (BD) forced expiratory volume in the first second (FEV1) < 50% predicted.
Participants must be 40-80 years of age inclusive, at the time of signing informed consent form (ICF).
Participants who have a confirmed primary diagnosis of moderate to severe COPD.
Participants who are current or ex-smokers with a tobacco history of ≥ 10 pack-years.
Participants who have a documented stable regimen of triple therapy or dual therapy for
≥ 3 months prior to enrolment.
Body mass index within the range 18 to 40 kg/m2 (inclusive).
Exclusion Criteria:
As judged by the investigator, any evidence of any active medical or psychiatric condition or other reason (at SV1 [screening] and SV3 [pre-dose]) which in the investigator's opinion makes it undesirable for the participant to participate in the study.
Current diagnosis of asthma or past diagnosis of asthma which persisted beyond the age of 25 years.
Clinically important pulmonary disease other than COPD.
Any other clinically relevant abnormal findings on physical examination, laboratory testing including haematology, coagulation, serum chemistry, or urinalysis; or chest CT scan at screening or randomisation, which in the opinion of the investigator or medical monitor may compromise the safety of the participant in the study or interfere with evaluation of the study intervention or reduce the participant's ability to participate in the study.
History of a clinically significant infection (viral, bacterial, or fungal; defined as requiring systemic antibiotics, antiviral, or antifungal medication for > 7 days) within 4 weeks prior to SV3 (Day 1) (including unexplained diarrhoea) or clinical suspicion of infection at time of dosing.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
AstraZeneca Clinical Study Information Center
Phone
1-877-240-9479
Email
information.center@astrazeneca.com
Facility Information:
Facility Name
Research Site
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33765
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
DeLand
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Lake Wales
State/Province
Florida
ZIP/Postal Code
33853
Country
United States
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33186
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32825
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Winter Park
State/Province
Florida
ZIP/Postal Code
32789
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chicago Ridge
State/Province
Illinois
ZIP/Postal Code
60415
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chesterfield
State/Province
Missouri
ZIP/Postal Code
63017
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Saint Charles
State/Province
Missouri
ZIP/Postal Code
63301
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
New Windsor
State/Province
New York
ZIP/Postal Code
12553
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Gastonia
State/Province
North Carolina
ZIP/Postal Code
28054
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Kernersville
State/Province
North Carolina
ZIP/Postal Code
27284
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
New Bern
State/Province
North Carolina
ZIP/Postal Code
28562
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43215
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Choctaw
State/Province
Oklahoma
ZIP/Postal Code
73020
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Fort Mill
State/Province
South Carolina
ZIP/Postal Code
29707
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Amarillo
State/Province
Texas
ZIP/Postal Code
79106
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Buenos Aires
ZIP/Postal Code
C1121ABE
Country
Argentina
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Buenos Aires
ZIP/Postal Code
C1414AIF
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Research Site
City
Buenos Aires
ZIP/Postal Code
C1425BEN
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Research Site
City
Córdoba
ZIP/Postal Code
X5003DCE
Country
Argentina
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Ranelagh
ZIP/Postal Code
1886
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Research Site
City
San Fernando
ZIP/Postal Code
B1646EBJ
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Research Site
City
Dupnitsa
ZIP/Postal Code
2602
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Research Site
City
Haskovo
ZIP/Postal Code
6305
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ruse
ZIP/Postal Code
7000
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Research Site
City
Stara Zagora
ZIP/Postal Code
6000
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Research Site
City
Stara Zagora
ZIP/Postal Code
6003
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Research Site
City
Vratsa
ZIP/Postal Code
3000
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Research Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H1M 1B1
Country
Canada
Individual Site Status
Recruiting
Facility Name
Research Site
City
St Charles Borromee
State/Province
Quebec
ZIP/Postal Code
J6E 2B4
Country
Canada
Individual Site Status
Recruiting
Facility Name
Research Site
City
Trois-Rivières
State/Province
Quebec
ZIP/Postal Code
G8T 7A1
Country
Canada
Individual Site Status
Recruiting
Facility Name
Research Site
City
Quebec
ZIP/Postal Code
G1V 4G5
Country
Canada
Individual Site Status
Recruiting
Facility Name
Research Site
City
Quebec
ZIP/Postal Code
G3K 2P8
Country
Canada
Individual Site Status
Recruiting
Facility Name
Research Site
City
Aalborg
ZIP/Postal Code
9000
Country
Denmark
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hvidovre
ZIP/Postal Code
2650
Country
Denmark
Individual Site Status
Recruiting
Facility Name
Research Site
City
København NV
ZIP/Postal Code
2400
Country
Denmark
Individual Site Status
Recruiting
Facility Name
Research Site
City
Næstved
ZIP/Postal Code
4700
Country
Denmark
Individual Site Status
Recruiting
Facility Name
Research Site
City
Odense C
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Recruiting
Facility Name
Research Site
City
Vejle
ZIP/Postal Code
7100
Country
Denmark
Individual Site Status
Recruiting
Facility Name
Research Site
City
Berlin
ZIP/Postal Code
10119
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Frankfurt am Main
ZIP/Postal Code
60596
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Hamburg
ZIP/Postal Code
22299
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Homburg
ZIP/Postal Code
66421
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Immenhausen
ZIP/Postal Code
34376
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Koblenz
ZIP/Postal Code
56068
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Landsberg
ZIP/Postal Code
86899
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Leipzig
ZIP/Postal Code
04299
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Marburg
ZIP/Postal Code
35037
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Foggia
ZIP/Postal Code
71100
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Roma
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Verona
ZIP/Postal Code
37134
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Culiacán
ZIP/Postal Code
80200
Country
Mexico
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Guadalajara
ZIP/Postal Code
44100
Country
Mexico
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Guadalajara
ZIP/Postal Code
44670
Country
Mexico
Individual Site Status
Recruiting
Facility Name
Research Site
City
Mexico City
ZIP/Postal Code
3103
Country
Mexico
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Monterrey
ZIP/Postal Code
64310
Country
Mexico
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Monterrey
ZIP/Postal Code
64465
Country
Mexico
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Veracruz
ZIP/Postal Code
91910
Country
Mexico
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Zapopan
ZIP/Postal Code
45138
Country
Mexico
Individual Site Status
Recruiting
Facility Name
Research Site
City
Groningen
ZIP/Postal Code
9713 GH
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Research Site
City
Rotterdam
ZIP/Postal Code
3045 PM
Country
Netherlands
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Veldhoven
ZIP/Postal Code
5504 DB
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Research Site
City
Bielsko-Biała
ZIP/Postal Code
43-300
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chęciny
ZIP/Postal Code
26-060
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Karczew
ZIP/Postal Code
05-480
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Kraków
ZIP/Postal Code
31-011
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ksawerów
ZIP/Postal Code
95-054
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Proszowice
ZIP/Postal Code
32-100
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Sosnowiec
ZIP/Postal Code
41-200
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Staszów
ZIP/Postal Code
28-200
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Szczecin
ZIP/Postal Code
70-111
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Trzebnica
ZIP/Postal Code
55-100
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Warszawa
ZIP/Postal Code
01-456
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Cape Town
ZIP/Postal Code
7700
Country
South Africa
Individual Site Status
Recruiting
Facility Name
Research Site
City
Durban
ZIP/Postal Code
4001
Country
South Africa
Individual Site Status
Recruiting
Facility Name
Research Site
City
Durban
ZIP/Postal Code
4093
Country
South Africa
Individual Site Status
Recruiting
Facility Name
Research Site
City
Krugersdorp
ZIP/Postal Code
1739
Country
South Africa
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Lenasia
ZIP/Postal Code
1827
Country
South Africa
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Tygervalley
ZIP/Postal Code
7530
Country
South Africa
Individual Site Status
Recruiting
Facility Name
Research Site
City
Vereeniging
ZIP/Postal Code
1935
Country
South Africa
Individual Site Status
Recruiting
Facility Name
Research Site
City
Granada
ZIP/Postal Code
18014
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Málaga
ZIP/Postal Code
29010
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Mérida
ZIP/Postal Code
06800
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Santander
ZIP/Postal Code
39008
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Adana
ZIP/Postal Code
01330
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ankara
ZIP/Postal Code
06620
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Research Site
City
Istanbul
ZIP/Postal Code
34854
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Research Site
City
Istanbul
ZIP/Postal Code
34890
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Research Site
City
Izmir
ZIP/Postal Code
35360
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Research Site
City
Mersin
ZIP/Postal Code
33343
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Research Site
City
Bradford
ZIP/Postal Code
BD9 6RJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Cambridge
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Cottingham
ZIP/Postal Code
HU16 5JQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Dundee
ZIP/Postal Code
DD1 9SY
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Glasgow
ZIP/Postal Code
G12 0YN
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
London
ZIP/Postal Code
EC1M 6BQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
London
ZIP/Postal Code
NW3 2QG
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Nottingham
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Rotherham
ZIP/Postal Code
S65 2QL
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Salford
ZIP/Postal Code
M6 8HD
Country
United Kingdom
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Salford
ZIP/Postal Code
M6 8HD
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Wakefield
ZIP/Postal Code
WF1 4DG
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
York
ZIP/Postal Code
YO24 3WX
Country
United Kingdom
Individual Site Status
Recruiting
12. IPD Sharing Statement
Learn more about this trial
An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
We'll reach out to this number within 24 hrs